HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Feb. 19, 2019 (HealthDay News) -- The multigene expression test Oncotype DX (ODX) is not cost-effective for women with breast cancer who are at low risk for recurrence, according to research published online Jan. 22 in the Journal of the National Comprehensive Cancer Network.
Shi-Yi Wang, M.D., Ph.D., from the Yale University School of Public Health in New Haven, Connecticut, and colleagues created models to calculate costs and quality-adjusted life-years (QALYs) gained over the lifetime for women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, lymph node-negative breast cancer. Data from the Connecticut Tumor Registry were used to identify 2,245 patients diagnosed from 2011 through 2013. These patients were classified into three clinical risk groups based on the PREDICT risk calculator.
The researchers found that approximately 82.5 percent of patients were low-risk, 11.9 percent were intermediate-risk, and 5.6 percent were high-risk. For all risk groups, ODX had an incremental cost-effectiveness ratio (ICER) of $62,200 per QALY for patients aged 60 years. However, ICERs varied across clinical risk groups and ranged from $124,600 per QALY in the low-risk group to $28,700 per QALY in the intermediate-risk group and $15,700 per QALY in the high-risk group. Further, ICER was sensitive to patient age; for patients aged 45 to 75 years, it ranged from $77,100 to $344,600 per QALY in the PREDICT low-risk group and was lower than $100,000 per QALY in the intermediate-risk and high-risk groups.
"ODX is not cost-effective for women with clinical low-risk breast cancer, which constitutes most patients with ER-positive disease," the authors write.
Several authors disclosed financial ties to pharmaceutical and medical device companies.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 27, 2022